LOS ANGELES–(BUSINESS WIRE)–Lundin
Law PC, a shareholder rights firm, announces a class action lawsuit
against Endologix Inc. (“Endologix” or the “Company”) (Nasdaq: ELGX)
concerning possible violations of federal securities laws. Investors who
purchased or otherwise acquired Endologix shares between August 2, 2016
and November 16, 2016 inclusive (the “Class Period”), are encouraged to
contact the firm in advance of the March 6, 2017
lead plaintiff motion deadline.

To participate in this class action lawsuit, please click
here, or call Brian Lundin, Esquire, of Lundin Law PC, at
888-713-1033, or e-mail him at [email protected].

No class has been certified in the above action yet. Until certification
occurs, you are not represented by an attorney. You may choose to take
no action and remain a passive class member.

Endologix’s endovascular aneurysm sealing system for treating infrarenal
abdominal aortic aneurysms is Nellix. Endologix noted that it would
approve the original Nellix system used in the Nellix investigational
device exemption (IDE) clinical trial, the EVAS FORWARD-IDE Study.
However, Endologix disclosed that the FDA requested a follow-up on
patients in the EVAS-FORWARD-IDE study to evaluate Nellix.

On December 27, 2016 Endologix stated that it was temporarily barring
AFX Endovascular AAA System shipments, due to a manufacturing
investigation. Upon disclosing this information to the investing public,
Endologix stock fell sharply, causing shareholders severe harm.

Lundin Law PC was established by Brian Lundin, a securities litigator
based in Los Angeles dedicated to upholding shareholders’ rights.

This press release may be considered Attorney Advertising in some
jurisdictions under the applicable law and ethical rules.